understanding arnis roberto ferrari资料.pdf

该【understanding arnis roberto ferrari资料 】是由【cj83252951】上传分享，文档一共【2】页，该文档可以免费在线阅读，需要了解更多关于【understanding arnis roberto ferrari资料 】的内容，可以使用淘豆网的站内搜索功能，选择自己适合的文档，以下文字是截取该文章内的部分文字，如需要获得完整电子版，请下载此文档到您的设备，方便您编辑和打印。CardioPulse1397Chief,HarvardHeartLetter),DukeClinicalResearchInstitute(clinicalBoehringerIngelheim,Bristol-MyersSquibb,Chiesi,Eisai,Ethicon,mittees),HMPGlobal(EditorinChief,JournalofForestLaboratories,Idorsia,Ironwood,Ischemix,Lilly,Medtronic,InvasiveCardiology),JournaloftheAmericanCollegeofCardiologyPhaseBio,Pfizer,Regeneron,Roche,SanofiAventis,Synaptic,The(GuestEditor;AssociateEditor),Medtelligence/ReachMD(CMEsteer-pany;Royalties:Elsevier(Editor,Cardiovascularmittees),PopulationHealthResearchInstitute(fortheIntervention:ACompaniontoBraunwald’sHeartDisease);SiteCo-mittee,mittee,steeringInvestigator:Biotronik,BostonScientific,(nowcommittee,andUSAnationalco-leader,fundedbyBayer),SlackAbbott),Svelte;Trustee:AmericanCollegeofCardiology;UnfundedPublications(ChiefMedicalEditor,CardiologyToday’sIntervention),Research:FlowCo,Fractyl,Merck,NovoNordisk,PLxPharma,SocietyofCardiovascularPatientCare(Secretary/Treasurer),(mittees);Other:ClinicalCardiology(DeputyEditor),NCDR-mitteeReferencesDownloadedfromhttps://academic./eurheartj/article-abstract/40/18/1397/5486153bygueston08May2019(Chair),mittee(Chair);ReferencesareavailableassupplementarymaterialatEuropeanHeartResearchFunding:Abbott,Amarin,Amgen,AstraZeneca,Bayer,:‘goodandbad’oftheneuroendocrineresponseinheartfailureisabalancingactdiscussedandillustratedbyRobertoFerrari,Jose′Silva-Cardosa,andMariaCandidaFonsecaTheresultsofthePARADIGM-HFstudyhaveshedanewlightonthetreatmentofheartfailure(HF).1PARADIGMisatrialof‘threefirsts’:-existingdrug,insteadofaddingittotheusualtherapy;;,insteadofantagonizing,(c)representsarealchangeinPARADIGMandexplainssubstanceP,calcitoningene-relatedpeptide,andothers,allknowntotherobustresultsofPARADIGM-essfulplayaroleincongestiveheartfailure(CHF).Consequently,,theneuroendocrineactivationinHFwasisapharmacologicalbiotargetinCHF(andnotonly).‘dogma’wastoantagonizeitandresearchtothegradualincreaseofplasmaconcentrationofallthissubstratehasproduceddifferentdrugstocounteracttheincreasedrenin–angio-,angiotensinreceptor-neprylisininhibitors(ARNIs)recruit-Figure1,however,showsinanextremelysimplemanner,thatingthe‘good’vasodilatoryanddiureticinfluencescontributetore-thebody’plexand,atbalancetheneuroendocrineactivationtoHF(Figure3).Thepres-least,twodistinctandoppositesystemsareactivated:-:‘thegoodandthebad’.However,inItfollowsthatsacubitril/valsartanrepresentsashiftinHFmedicalHF,withprogressionofthedisease,waterretentionandvasocon-therapywhich,foryears,hasbeendirectedtocounteractthe‘bad’strictionevokedbythe‘bad’ehormoneswithangiotensinconvertingenzymeinhibitors,angiotensinthe‘good’natriureticandvasodilatoryinfluencesresultinginadis-IIinhibitors,antialdosteronedrugs,andbeta-,responsiblefortheworseningofsymptomsandthe‘good’andblocks,inpartatleast,the‘bad’,itreinstatesamorephysiologicalneuroendo-Figure2showsthattheintroductionofsacubitrilinhibitsneprylisin,acrinebalanceresultinginimprovementofnaturaldiuresis,reductionofubiquitousneutralendopeptidasethatdegradesseveralpeptidessuchperipheralresistance,andbloodpressurewithameliorationofsymp-asatrialnatriureticpeptides(ANPs),angiotensinII,bradykinin,tomsandprognosis(Figure4).1398CardioPulseDownloadedfromhttps://academic./eurheartj/article-abstract/40/18/1397/5486153bygueston08May2019RobertoFerrariMDDepartmentofCardiologyandLTTACentre,MariaCandidaFonsecaJoséSilva-CardosoUniversityHospitalofFerraraandMariaCeciliaHospital,HeartFailureUnit,DepartmentofCardiology,GVMCare&Research,Cotignola(RA),ItalyInternalMedicineDepartment,FacultyofMedicine,ChairofCardiologyS?oFranciscoXavierHospital–CINTESIS-CenterforHealthAziendaOspedaliero-UniversitariadiFerraraWesternLisbonHospitalCentre(CHLO),TechnologyandServicesResearch,OspedalediConaLisbon,PortugalandNOVAMedicalSchool,UniversityofPorto,S?oJo?oViaAldoMoro8,44124(Cona)Ferrara,ItalyFacultyofMedicalSciences,MedicalCenter,Porto,:******@,:+390532239882Conflictofinterest:.-thatdevelopandmarkettestsand/ortreatmentsintheareaofHF)formitteemembershipandconsultingfromNovartisandServier;andHFconsulting,mitteesandgivingspeakerfeesfromCipla,Lupin,MerckSerono,.-C.:hasconsultedandreceivedspeakerfees,orinves-tigationalgrantsforAbbott,AstraZenecaPharmaceuticals,Bial,BoehringerIngelheim,Menarini,MerckSerono,MerckSharp&ReferencesDohme,Novartis,Orion,Pfizer,.:hasreceivedReferencesareavailableassupplementarymaterialatEuropeanHeartfeesfromNovartis,Servier,Orion,Roche,:AndrosTofield,:******@